Akbaraly Tasnime


Research Fellow Inserm

Contact: tasnime.akbaraly(at)

Phone: 04 67 14 36 86

Team 1: Cerebral aging and Neurodegenerative diseases

Team 3: Longevity and vitality

Dayanithi Govindan


Research Director CNRS

Contact: govindan.dayanithi(at)

Phone : 04 67 14 93 47

Team 1: Cerebral aging and Neurodegenerative diseases

Delprat Benjamin


Research Fellow CNRS

Contact: benjamin.delprat(at)

Phone: + 33/04 67 14 36 23

Team 2: "Endogenous neuroprotection in neurodegenerative diseases"

Desrumaux Catherine

silhouette f

Research Fellow Inserm

Contact: catherine.desrumaux-piazza(at)

Phone: 04 67 14 36 89

Team 6: "Environmental impact in Alzheimer's disease and related disorders"

Givalois Laurent


Research Fellow CNRS

Contact: laurent.givalois(at)

Phone: 04 67 14 38 14

Team 6: "Environmental impact in Alzheimer's disease and related disorders"

Lievens Jean-Charles


Research Fellow CNRS

Contact: jean-charles.lievens(at)

Phone: 04 67 14 32 85

Team 4: Huntington’s disease: Neurophysiopathology from drosophila to mice



Maschat Florence


Research Director CNRS

Contact: florence.maschat(at)

Phone: 33 (0)4 67 14 42 70

Team 4: Huntington’s disease: Neurophysiopathology from drosophila to mice

Collaborations : 

  • Medesis pharma (Private company - Baillargues - France)
  • Pr Michel Vignes (IBMM, University of Montpellier)
  • Pr Edwin Chan (University of Hong Kong)



Interview - 2013


Our research topics include two axes.

One concerns the study of Engrailed homeoprotein. The identification of the regulatory networks involving this transcription factor have been carried out using genomic scale approaches: chromatin immunoprecipitation experiments to isolate direct targets genes and two-hybrid experiments in yeast to identify Engrailed cofactors. Our team has recently focused on Engrailed implication in neurodevelopment, and the identification of genes regulated by Engrailed and its cofactor (Neuro-Goosberry) to better understand the role of Engrailed in the construction of the nerve cord of an embryo.

On the other hand, among the direct targets of Engrailed, we identified that the Huntingtin, whose human homolog is involved in Huntington's disease (a rare neurodegenerative disease), is directly activated by Engrailed. This allowed us to develop a different axis and identify a 23aa peptide P42 contained in the Huntingtin protein which presents protective properties of this disease in Drosophila but also in mice. Besides obtaining international patents, P42 recently obtained an orphan drug designation by the European Medicines Agency (EMA). We plan to further develop this axis to better understand the physiological role of P42 and the mechanisms of action of this peptide in a view of its development at therapeutic purposes.

Maurice Tangui


Research Director CNRS

Contact: tangui.maurice(at)

Phone: + 33/04 67 14 36 23

Team 2: "Endogenous neuroprotection in neurodegenerative diseases"

NATIONAL Collaborations

  • CNRS UMR 5088, Laboratoire d'Innovation Thérapeutique, Toulouse
  • CNRS UMR 7200, Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération, Strasbourg
  • CNRS UMR 5253, Ecole Nationale Supérieure de Chimie, Montpellier
  • INRA UMR 866, Dynamique Musculaire et Métabolisme, Montpellier
  • INSERM U 1051, Institut des Neurosciences de Montpellier, Montpellier
  • INSERM U 1191, Institut de Génomique Fonctionnelle, Montpellier
  • Société d'Accélération de Transfert de Technologie AxLR, Montpellier

INTERNATIONAL Collaborations

  • Department of Histology, Faculty of Medical Sciences, Havana, Cuba
  • Institute of Chemical Biology, Ilia State University, Tbilisi, Georgia
  • Anavex Life Sciences, New York, USA


Tangui has spent more than 25 years in the field of neurosciences, including behavioral and molecular neuropharmacology, sigma receptors, neuropeptides, neurosteroids, neurotrophic factors, drug addiction, normal/pathological aging models including Alzheimer’s and related disorders, and behavioral phenotyping of rodent models. His publication records include 125 scientifc articles, 210 communications at national or international meeting, 5 patents and 35 invited conferences.

Tangui is CNRS Research Director since ten years and held research positions at Institut National de La Santé et de la Recherche Médicale (INSERM) U336, U710, U1198 and Centre National de la Recherche Scientifique (CNRS) UMR5102 in Montpellier. Tangui is a Chemical Engineer from ENSCM, by training. He holds a Ph.D. In cellular and molecular biology with a speciality in neuropharmacology from the university of Montpellier in 1990 and spent two years as a post-doc fellow in the Jouveinal Research Institute (Fresnes, France) and the Departments of Neuropsychopharmacology at Nagoya University Hospital and of Chemical Pharmacology at Meijo University (Nagoya, Japan). Tangui initiated the creation of a CRO company, Amylgen, and has several collaborations with industry, through regular contracts or scientific advisory boards. He was recipient of the bronze medal from CNRS.

Perrier Véronique

perrier v

Research Fellow CNRS

Contact: veronique.perrier(at)

Phone: 04 67 14 33 87

Team 6: "Environmental impact in Alzheimer's disease and related disorders"


Recent collaborations:

  • Pr Liu J., Huazhong University of Science and Technology, Wuhan, China.
  • Dr. Robitzer M., Institut Charles Gehrard, Laboratoire MACS, Montpellier.
  • Dr. Bougard D., Etablissement Français du Sang, Laboratoire Transdiag, Montpellier.
  • Dr. Prevostel C., Institut de Recherche en Cancérologie de Montpellier, Montpellier.


After obtaining my PhD in the field of protein biochemistry at the Pasteur Institute of Paris (1997, Paris XI University, Orsay), I continued my education with a postdoctoral training on the innovative concept of  "prions", which are infectious proteins responsible of prion diseases. I joined the laboratory of Pr. S. Prusiner in the United States (San Francisco, CA, 1997-2000) to study the mecanisms of resistance of prions via the characterization of "dominant negative" polymorphisms in transgenic mice, as well as a new approach of structure-based drug design via molecular and cellular screenings.In 2000, I got a researcher position at the CNRS and I joined the laboratory of Pr. S. Lehmann (Institute of Human Genetics, Montpellier, 2001-2004). The identification of antibodies and molecules such as dendrimers having "anti-prion" properties in cell cultures, and the development of lentiviral vectors carrying "dominant negative" prion proteins to develop a gene therapy approach were the main work carried out during this period.Since 2005, I joined the laboratory INSERM U710-now U1198- headed by Dr. JM Verdier. My research theme focuses on the study of molecular mechanisms involved in neurodegenerative diseases. I identified a family of thienyl pyrimidine compounds that specifically induce oligomers of the pathological isoform of the prion protein, PrPSc. These compounds exhibit very interesting properties for the diagnosis of prions and the deprionization of blood (collaboration with EFS Midi-Pyrénées). Furthermore, one of the identified compounds is a molecule derived from α-tertiophenes, which are synthesized by plants and possessed powerful herbicidal properties. Currently, my research theme has evolved into the role of pesticides in neurodegenerative diseases especially Alzheimer's and prions.

Robine Jean-Marie

robine Demographer, Research Director Inserm, and Professor at EPHE
Cermes3 et MMDN (U1198), Associate Researcher, Ined (MSE)

Contact: jean-marie.robine(at)

Phone: 04 67 14 33 85

Team3: Longevity and vitality


Jean-Marie Robine is a Research Director at Inserm, the French National Institute of Health and Medical Research (, within the Cermes3 Research group in Paris and the Unit 710 in Montpellier ( where he heads the research team Biodemography of longevity and vitality. He is also a Study Director at the advanced school Ecole pratique des hautes études ( in Paris. He studies human longevity, with the aim of understanding the relations between health and longevity. In particular, he measures the impact that the increase in adult life durations may have on the health status of the elderly population.

Since its creation in 1989, he has been the coordinator of the International Network on Health Expectancy (REVES), which brings together more some 100 researchers worldwide ( He is the project leader of the Joint Action European Life and Health Expectancy Information System (, which provides analysis of disability-free life expectancies in the European Union (Healthy Life Years-HLY). He is co-responsible for the development of the International Database on Longevity (IDL) in association with the Max Planck Institute for Demographic Research (Rostock) and Ined (Paris). He is one of the principal investigators of the Genetic of Healthy Ageing project (GEHA) and the project leader of the healthy longevity project granted by AXA Research Fund: the Five-Country Oldest Old Project (5-COOP). He is one of the Directors of the new French Research Consortium on ageing and longevity (GDR CNRS 3662, 2014-2017).


Torrent i Mas Joan


Research Fellow Inserm

Contact: joan.torrent(at)

Phone: 04 67 14 33 87

Team 6: "Environmental impact in Alzheimer's disease and related disorders"